Jazuli Isyaku Bala

Jazuli Isyaku Bala

Auto-generated profile, based on publicly available information

Jazuli Isyaku Bala

Department of Hematology and Transfusion Medicine, Faculty of Clinical Sciences, Bayero University Kano, Aminu Kano Teaching Hospital Kano (AKTH), Kano, Nigeria

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Epidemiology and Health Data Insights
Verified
Journal Article
Closed access
IOIkemefula Oriaku
Ikemefula Oriaku
OOOluchi Okechukwu
Oluchi Okechukwu
OOObiageri Ihuarulam Okeoma
Obiageri Ihuarulam Okeoma
CGChidinma Gab-Obinna
Chidinma Gab-Obinna
JBJazuli Isyaku Bala
Jazuli Isyaku Bala
OAOluwabusayo Olufunke Awoyomi
Oluwabusayo Olufunke Awoyomi
Artificial intelligence (AI) is increasingly shaping modern healthcare by enabling data-driven decision-making, improving diagnostic accuracy, and optimizing resource use. In transfusion medicine, AI offers substantial opportunities to enhance donor management, automate blood typing and compatibility testing, strengthen inventory forecasting, and support early detection of transfusion-related complications. This review summarizes current applications of AI technologies—including machine learning, deep learning, natural language processing, computer vision, and predictive analytics—and evaluates their impact across laboratory, clinical, and operational domains. Emerging innovations such as precision transfusion, patient digital twins, multi-omics integration, and federated learning highlight AI’s potential to advance personalized and interconnected transfusion practices. However, successful implementation requires addressing challenges related to data heterogeneity, algorithmic bias, privacy and ethical considerations, and evolving regulatory requirements. Establishing rigorous validation standards and promoting interdisciplinary collaboration will be essential to ensure that AI improves the safety, efficiency, and sustainability of transfusion medicine.

13 January 2026 in Australian Journal of Biomedical Research
Verified
Journal Article
Open access
PDF file
CGChidinma Lorretta Gab-Obinna
Chidinma Lorretta Gab-Obinna
IOIkemefula Oriaku
Ikemefula Oriaku
OOObiageri Ihuarulam Okeoma
Obiageri Ihuarulam Okeoma
AOAdepeju Kafayat Olowookere
Adepeju Kafayat Olowookere
EOEnobong Edoabasi Obong
Enobong Edoabasi Obong
JBJazuli Isyaku Bala
Jazuli Isyaku Bala
Background: Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) remain major global health burdens. Ex vivo gene-editing therapies aim to achieve durable fetal hemoglobin (HbF) induction or direct mutation correction. Methods: We systematically reviewed clinical studies of CRISPR-Cas9 or base-editing therapies for SCD and TDT (MEDLINE, EMBASE, Web of Science, ClinicalTrials.gov, conference proceedings; 2010–03 December 2025). Eleven studies (>170 treated patients) reporting post-infusion outcomes were included. Results: All therapies produced robust, pancellular HbF (30–65%) and total hemoglobin in/near the normal range. In TDT (n > 100 evaluable), transfusion independence (≥12 months, Hb ≥9 g/dL) was achieved in 89–100% across platforms, sustained up to >4 years. In SCD (n > 60 evaluable), adjudicated vaso-occlusive crises were eliminated for ≥12 months in ≥97% of patients treated with exagamglogene autotemcel and 100% in smaller cohorts (EDIT-301, BEAM-101). No graft failures occurred. Serious adverse events and one death were attributable to busulfan conditioning, not editing. No therapy-related malignancies or confirmed harmful off-target edits have been reported, although follow-up remains limited (median ~18 months, longest >4 years). Conclusion: Current evidence from phase 1–3 trials demonstrates that ex vivo gene editing can achieve functional cure for many patients with TDT and severe SCD. Conditioning-related toxicity, limited long-term safety data, and delivery complexity remain critical barriers to broader implementation.